Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHINE trial of BHV-7000 in idiopathic generalized epilepsy with generalized tonic-clonic seizures
NL-OMON60949Phase 3Completed
- Sponsor
- Biohaven Ltd.
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic epilepsy (IGE) comparing BHV-7000 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Time to the second day with a generalized tonic-clonic seizure. Started Nov 2024; status: completed.
02
Drugs
opakalim
03
Conditions
idiopathic epilepsy (IGE)
Beyond the preview
Go deeper on NL-OMON60949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60949.